Janney Capital Upgrades DepoMed Inc (DEPO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50
May 12, 2015 12:42 PM EDTRoth Capital analyst Scott Henry trimmed his price target on DepoMed Inc (NASDAQ: DEPO) to $28.50 (from $30.00) following Q1 results but maintained a Buy rating. The firm views today's 18% sell-off as a "over-reaction."
Henry commented, "DEPO reported 1Q15 results that were at the lower end... More
